34 Honkoop, P. (1997) Mitochondrial injury. Lessons from the fialuridine trial. *Drug Safety* 17, 1–7

35 Medical Economics Company (2000) Rezulin® monograph. In: *Physician's Desk Reference* (54th edn), pp. 2278–2282

36 Anon (2000), Avandia, Actos to accelerate market growth with Rezulin's withdrawal. *The Pink Sheet*, 62, No.13

37 Jo, M. *et al.* (2000) Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. *Nat. Med.* 6, 564–567

38 Walczak, H. *et al.* (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand *in vivo*. *Nat. Med.* 5, 157–163

39 Ashkenazi, A. *et al.* (1999) Safety and antitumor activity of recombinant soluble Apo2 ligand. *J. Clin. Invest.* 104, 155–162

40 Davila, J.C. *et al.* (1998) Predictive value of *in vitro* model systems in toxicology. *Annu. Rev. Pharmacol. Toxicol.* 38, 63–96

41 Brusick, D. (1994) Genetic Toxicology. In *Principles and Methods of Toxicology* (Hayes, A. W., ed.), pp. 545–577, Raven Press

42 Parkinson, A. (1996) An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials. *Toxicol. Pathol.* 24, 45–57

43 Obach, R.S. (1999) Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of *in vitro* half-life approach and nonspecific binding to microsomes. *Drug Metab. Dis.* 27, 1350–1359

44 Smith, D.A. and van de Waterbeemd, H. (1999) Pharmacokinetics and metabolism in early drug discovery. *Curr. Opin. Chem. Biol.* 3, 373–378

45 Davit, B. *et al.* (1999) FDA evaluations using *in vitro* metabolism to predict and interpret *in vivo* metabolic drug–drug interactions: Impact on labeling. *J. Clin. Pharmacol.* 39, 899–910

46 Benfenati, E. and Gini, G. (1997) Computational predictive programs (expert systems) in toxicology. *Toxicology* 119, 213–225

47 Richard, A.M. (1994) Application of SAR methods to non-congeneric databases associated with carcinogenicity and mutagenicity: issues and approaches. *Mutat. Res.* 305, 73–97

48 Richard, A.M. (1998) Structure-based methods for predicting mutagenicity and carcinogenicity: are we there yet? *Mutat. Res.* 400, 493–507

49 Dearden, J.C. *et al.* (1997) The development and validation of expert systems for predicting toxicity. *ATLA* 25, 223–252

50 Greene, N. (1997) Computer software for risk assessment. *J. Chem. Inf. Comput. Sci.* 37, 148–150

51 Greene, N. *et al.* (1999) Knowledge-based expert systems for toxicity and metabolism prediction: DEREK, StAR and METEOR. *SAR QSAR Environ. Res.* 10, 299–314

52 Ridings, J.E. *et al.* (1996) Computer prediction of possible toxic action from chemical structure: an update on the DEREK system. *Toxicology* 106, 267–279

53 Barratt, M.D. and Langowski, J.J. (1999) Validation and subsequent development of the DEREK skin sensitization rulebase by analysis of the BgVV list of contact allergens. *J. Chem. Inf. Comput. Sci.* 39, 294–298

54 Benigni, R. (1997) The first US National Toxicology Program exercise on the prediction of rodent carcinogenicity: definitive results. *Mutat. Res.* 387, 35–45

55 Zeiger, E. *et al.* (1996) Prediction of Salmonella mutagenicity. *Mutagenesis* 11, 471–484

56 Rosenkranz, H.S. *et al.* (1999) Development, characterization and application of predictive toxicology models. *SAR QSAR Environ. Res.* 10, 277–298

57 Pollack, N. *et al.* (1999) Chemical diversity approach for evaluating mechanistic relatedness among toxicological phenomena. *SAR QSAR Environ. Res.* 10, 533–543

58 Matthews, E.J. and Contrera, J.F. (1998) A new highly specific method for predicting the carcinogenic potential of pharmaceuticals in rodents using enhanced MCASE QSAR-ES Software. *Reg. Toxicol. Pharmacol.* 28, 242–264

59 The Toxicologist (2000) Abstracts of the 39th Annual meeting of the Society of Toxicology. *Toxicol. Sci.* 54 (Suppl.), No. 1

60 Pennie, W.D. *et al.* (2000) The principles and practice of toxicogenomics: applications and opportunities. *Toxicol. Sci.* 54, 277–283

61 Steiner, S. and Anderson, N.L. (2000) Expression profiling in toxicology – potentials and limitations. *Toxicol. Lett.* 112–113, 467–471

Corrigendum

Please note a correction to the company mentioned in the legend for Fig. 10 in the article *Can peptides be mimicked?* by Nigel R.A. Beeley, published in *Drug Discovery Today* (2000) 5(8), 354–363. The legend should have read:

Figure 10. *A comparison between Hirschmann's sugar-based somatostatin agonists with an early Sandoz (now Novartis, Basel, Switzerland) benzodiazepinone agonist.*

The author would like to apologize for this inaccuracy and for any misunderstandings that this might have caused.

 1359-6446/00/$ – see front matter PII: S1359-6446(00)01569-5